BIRC5 and neoplasm: LLC1 tumours highly express the tumour-associated antigen, survivin,35 which has been successfully targeted by various immunotherapeutic approaches.36 We confirmed survivin expression in LLC1-IFNAR1−/− cells (Fig. S3) and hypothesised a potential induction of anti-tumour T cells due to VSV-GP therapy would include a population of survivin-specific T cells.